Overview
The aim of this study is to examine the efficacy and adverse events in the following 3 groups in rheumatoid arthritis patients:
- Sarilumab treatment for 12 months
- Tocilizmab treatment for 12 months
- Abatacept treatment for 12 months
Eligibility
Inclusion Criteria:
・RA patients
Exclusion Criteria:
- Not RA patients
- RA patients who are allergic to the drugs, refused to do this research, or who are pregnant